Esperion Therapeutics, Inc. (ESPR) financial statements (2022 and earlier)

Company profile

Business Address 3891 RANCHERO DRIVE, SUITE 150
ANN ARBOR, MI 48108
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments259305201136200212212
Cash and cash equivalents20930516637343877
Short-term investments50 3599166173135
Receivables23      
Inventory, net of allowances, customer advances and progress billings3416     
Inventory3416     
Other undisclosed current assets1225117422
Total current assets:329346212143204214214
Noncurrent Assets
Operating lease, right-of-use asset262
Property, plant and equipment1111011
Long-term investments and receivables   0733180
Long-term investments   0733180
Intangible assets, net (including goodwill)0000000
Intangible assets, net (excluding goodwill)0000000
Restricted cash and investments50      
Total noncurrent assets:53731743281
TOTAL ASSETS:382353214143278245296
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities487741482262
Accounts payable185229452051
Accrued liabilities3025123111
Deferred revenue622
Debt  0 122
Other undisclosed current liabilities201623161182
Total current liabilities:7394666433166
Noncurrent Liabilities
Long-term debt and lease obligation2591831  13
Long-term debt, excluding current maturities258179   13
Operating lease, liability131
Liabilities, other than long-term debt11     
Deferred revenue1  
Other liabilities 1     
Other undisclosed noncurrent liabilities246171127    
Total noncurrent liabilities:505355128  13
Total liabilities:5794491946433178
Stockholders' equity
Stockholders' equity attributable to parent(197)(96)2079245229287
Common stock0000000
Treasury stock, value(55)(55)     
Additional paid in capital964798715678642458442
Accumulated other comprehensive income (loss)(0) 0(0)(1)(0)(0)
Accumulated deficit(1,106)(839)(695)(598)(396)(229)(154)
Total stockholders' equity:(197)(96)2079245229287
TOTAL LIABILITIES AND EQUITY:382353214143278245296

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues78228148    
Gross profit:78228148    
Operating expenses(305)(349)(241)(205)(169)(76)(50)
Operating loss:(227)(121)(93)(205)(169)(76)(50)
Nonoperating income
(Other Nonoperating income)
4143221
Interest and debt expense(46)(23)(8) (0)(0)(1)
Net loss available to common stockholders, diluted:(269)(144)(97)(202)(167)(75)(50)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(269)(144)(97)(202)(167)(75)(50)
Comprehensive loss:(269)(144)(97)(202)(167)(75)(50)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)01(1)0(0)
Comprehensive loss, net of tax, attributable to parent:(269)(144)(97)(201)(168)(75)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: